OBJECTIVE: To determine the frequency of and risk factors for major adverse drug reactions (MADRs) associated with anti-tuberculosis treatment at a tuberculosis (TB) referral hospital in the Republic of Korea. METHODS: Data from an ongoing natural history cohort study were analyzed for permanent regimen changes due to adverse drug reactions and confirmed by chart review. RESULTS: Among 655 subjects, there were 132 MADRs in 112 (17%) subjects. The most common MADRs were gastrointestinal (n = 53), musculoskeletal (n = 22), psychiatric (n = 10), visual (n = 9) and peripheral neuropathic (n = 8). MADRs were more frequent in subjects being treated with second-line regimens (16%) compared to first-line regimens (2.5%). Drugs frequently associated with MADRs were amikacin (3/10, 30%), linezolid (8/29, 28%), para-aminosalicylic acid (47/192, 24%), pyrazinamide (31/528, 5.8%), macrolides (2/44, 4.5%) and cycloserine (12/272, 4.4%). Fluoroquinolones accounted for a single MADR (1/377, 0.003%), despite widespread usage. In multivariate analysis, infection with multi- or extensively drug-resistant disease and previous history of anti-tuberculosis treatment were risk factors for MADR, with adjusted hazard ratios of respectively 2.2 (P = 0.02) and 1.6 (P = 0.04). CONCLUSION: MADRs are common during anti-tuberculosis chemotherapy in this population, occurring in more than one in six subjects. New and less toxic agents to treat drug-resistant TB are urgently needed.
OBJECTIVE: To determine the frequency of and risk factors for major adverse drug reactions (MADRs) associated with anti-tuberculosis treatment at a tuberculosis (TB) referral hospital in the Republic of Korea. METHODS: Data from an ongoing natural history cohort study were analyzed for permanent regimen changes due to adverse drug reactions and confirmed by chart review. RESULTS: Among 655 subjects, there were 132 MADRs in 112 (17%) subjects. The most common MADRs were gastrointestinal (n = 53), musculoskeletal (n = 22), psychiatric (n = 10), visual (n = 9) and peripheral neuropathic (n = 8). MADRs were more frequent in subjects being treated with second-line regimens (16%) compared to first-line regimens (2.5%). Drugs frequently associated with MADRs were amikacin (3/10, 30%), linezolid (8/29, 28%), para-aminosalicylic acid (47/192, 24%), pyrazinamide (31/528, 5.8%), macrolides (2/44, 4.5%) and cycloserine (12/272, 4.4%). Fluoroquinolones accounted for a single MADR (1/377, 0.003%), despite widespread usage. In multivariate analysis, infection with multi- or extensively drug-resistant disease and previous history of anti-tuberculosis treatment were risk factors for MADR, with adjusted hazard ratios of respectively 2.2 (P = 0.02) and 1.6 (P = 0.04). CONCLUSION: MADRs are common during anti-tuberculosis chemotherapy in this population, occurring in more than one in six subjects. New and less toxic agents to treat drug-resistant TB are urgently needed.
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2007-12 Impact factor: 2.373
Authors: T Törün; G Güngör; I Ozmen; Y Bölükbaşi; E Maden; B Biçakçi; G Ataç; T Sevim; K Tahaoğlu Journal: Int J Tuberc Lung Dis Date: 2005-12 Impact factor: 2.373
Authors: Wing Wai Yew; Chi Kuen Chan; Chi Chiu Leung; Chi Hung Chau; Cheuk Ming Tam; Poon Chuen Wong; Joseph Lee Journal: Chest Date: 2003-10 Impact factor: 9.410
Authors: Christie Y Jeon; Soo Hee Hwang; Jin Hong Min; D Rebecca Prevots; Lisa C Goldfeder; Hyeyoung Lee; Seok Yong Eum; Doo Soo Jeon; Hyung Seok Kang; Jin Hee Kim; Byoung Ju Kim; Dae Yeon Kim; Steven M Holland; Seung Kyu Park; Sang Nae Cho; Clifton E Barry; Laura E Via Journal: Clin Infect Dis Date: 2008-01-01 Impact factor: 9.079
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: Jae Chol Choi; Song Yong Lim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Nam Yong Lee; Young Kil Park; Gil Han Bai; Won Jung Koh Journal: J Korean Med Sci Date: 2007-08 Impact factor: 2.153
Authors: Ben Gold; Maneesh Pingle; Steven J Brickner; Nilesh Shah; Julia Roberts; Mark Rundell; W Clay Bracken; Thulasi Warrier; Selin Somersan; Aditya Venugopal; Crystal Darby; Xiuju Jiang; J David Warren; Joseph Fernandez; Ouathek Ouerfelli; Eric L Nuermberger; Amy Cunningham-Bussel; Poonam Rath; Tamutenda Chidawanyika; Haiteng Deng; Ronald Realubit; J Fraser Glickman; Carl F Nathan Journal: Proc Natl Acad Sci U S A Date: 2012-09-10 Impact factor: 11.205
Authors: María Luisa Aznar; Ariadna Rando Segura; María Milagros Moreno; Mateu Espasa; Elena Sulleiro; Cristina Bocanegra; Eva Gil Olivas; Arlete Nindia Eugénio; Adriano Zacarias; Domingos Katimba; Estevao Gabriel; Jacobo Mendioroz; Maria Teresa López García; Tomas Pumarola; María Teresa Tórtola; Israel Molina Journal: Am J Trop Med Hyg Date: 2019-09 Impact factor: 2.345
Authors: Nneka N Ibekwe; John B Nvau; Peters O Oladosu; Auwal M Usman; Kolo Ibrahim; Helena I Boshoff; Cynthia S Dowd; Abayomi T Orisadipe; Olapeju Aiyelaagbe; Akinbo A Adesomoju; Clifton E Barry; Joseph I Okogun Journal: J Ethnopharmacol Date: 2014-06-06 Impact factor: 4.360
Authors: Tao Zhang; Jian Du; Xiaoyan Yin; Fuzhong Xue; Yanxun Liu; Runzi Li; Cheng Luo; Liang Li; Xiujun Li Journal: Int J Environ Res Public Health Date: 2015-12-29 Impact factor: 3.390
Authors: Wael A Alghamdi; Abdullah Alsultan; Mohammad H Al-Shaer; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; Stephan Schmidt; Scott K Heysell; Russell R Kempker; J Peter Cegielski; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191